Targeted Oncology· @TargetedOnc · X·· 1 天前评分70
正文 · 原文
A fascinating VOLGA finding:
EV + durvalumab improved EFS and OS, while adding tremelimumab improved EFS but did not meet OS significance.
Do we really need CTLA-4 intensification?
More treatment isn’t necessarily better. Toxicity and absolute benefit matter. #ESMO26
77 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
LBA2按 Presidential Symposium I 对上
Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgVOLGA
https://esmocongress.esmo.org来源：Targeted Oncology · x.com